Tepotinib

Drug Profile

Tepotinib

Alternative Names: EMD-1214063; MSC-2156119; MSC-2156119J

Latest Information Update: 16 Jul 2017

Price : $50

At a glance

  • Originator EMD Serono; Merck KGaA; Merck Serono
  • Class Antineoplastics; Nitriles; Piperidines; Pyridazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Hepatocellular carcinoma; Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 05 Jun 2017 Phase-II clinical trials in Adenocarcinoma (Late-stage disease, Second-line therapy or greater, Treatment-experienced) in USA, Germany, Italy, Poland (PO) (NCT02864992) (EudraCT2015-005696-24)
  • 02 Jun 2017 Interim efficacy and adverse events data from a phase II trial in Adenocarcinoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Efficacy and adverse events data from a phase-Ib/II trial in Hepatocellular carcinoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top